Reports of substandard medicines: a lexicographic analysis of the Brazilian Health Surveillance Report System

  • Mayra Bruna Fedalto Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil
  • Antonio Eduardo Matoso Mendes Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil
  • Fernanda Stumpf Tonin Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
  • Fernando Fernandez-Llimos Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal
  • Roberto Pontarolo Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil
Keywords: Bibliometrics., Public Health Surveillance, Substandard Medicine (Substandard Drugs)

Abstract

Regulatory agencies are responsible for collecting and evaluating spontaneous reports of suspected problems related to medications, including those from substandard medicines (SM). Objectives: The aim was to evaluate the profile of SM reports submitted to the Brazilian Health Surveillance Notification System (Notivisa) and classify these reports objectively by means of lexicographic analysis. Methods: Was extracted all SM reports available in Notivisa during the period 1 January 2007 to 31 December 2017. Descriptive statistics were performed and the reasons for SM reporting were standardized (using OpenRefine and Microsoft Excel). The following analyses were performed using IRAMuTeQ 0.7 alpha2: lexicographic analysis to obtain the frequency of active words; descending hierarchical classification (DHC) to categorize the active words into lexical classes; factorial correspondence analysis (FCA) to obtain graphs of the classes. Approved by the Ethics Committee of the Hospital do Trabalhador/SES/PR CAAE 81873417.3.0000.5225 (protocol number: 2.506.594). Results: A total of 61,775 reports were analyzed, most of them reported by hospitals (46%). The DHC of the reasons for SM produced four classes visualized in the FCA: (i) packaging problems (16%) mainly leakages/opening issues; (ii) inadequate drug identification (22%), such as illegible label information; (iii) stability and contamination issues (11%) such as presence of particles; (iv) damaged tablets/blisters (23%) mainly broken tablets. Most SM (52%) were solutions for parenteral use; sodium chloride (9%), glucose and dipyrone (3%) were the products with most complaints. Conclusions: The reasons for SM reporting can be objectively classified into classes that represent the main problems submitted to Notivisa. This classification could guide the standardization of SM reporting and contribute to improving surveillance reporting systems worldwide.

Author Biographies

Mayra Bruna Fedalto, Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil

Programa de Pós-graduação em Ciências Farmacêuticas

Antonio Eduardo Matoso Mendes, Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil

Programa de Pós-graduação em Ciências Farmacêuticas

Fernanda Stumpf Tonin, Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

2Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

Fernando Fernandez-Llimos, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

3Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.

Published
2021-12-06
Section
Research Article